June 2, 2017 (Montréal, QC) ? As Cystic Fibrosis Awareness Month comes to an end, Cystic Fibrosis Canada is extremely disappointed to learn that those living with cystic fibrosis (CF) in Québec will not have access to lumacaftor/ivacaftor (ORKAMBI™) – a life-changing medication – through the list of medications reimbursed by the Régie d’assurance maladie du Québec (RAMQ), because of the recent recommendation issued by the Institut national d’excellence en santé et en services sociaux (INESSS).Read More
All media inquiries can be directed to firstname.lastname@example.org or by calling 1-800-378-2233.
May is cystic fibrosis (CF) Awareness Month, and Cystic Fibrosis Canada (CF Canada) is launching a campaign to ensure Canadians are aware of the significant challenges around access to drugs many with CF are currently facing. As research breakthroughs and new drugs that can vastly improve the quality and length of life for people with CF become available, it is essential those who can benefit gain access to these advances in health care.Read More
Health Canada’s approval of ORKAMBITM for children with cystic fibrosis (CF) aged 6 to 11 years means that they could stand a better chance at living a longer, healthier life. Approximately 267 Canadian children with CF could benefit from access to this breakthrough treatment.Read More
Cystic Fibrosis Canada is extremely disappointed that people with cystic fibrosis (CF) in British Columbia will not be able to access lumacaftor/ivacaftor (ORKAMBI™) - a potentially life-changing drug - through the BC Pharmacare program, due to a recent decision to “close the books” on ORKAMBI™.Read More
Cystic Fibrosis Canada is disappointed that people with cystic fibrosis (CF) in Canada are going to have wait even longer to gain access to ORKAMBI™, a potentially life-changing drug.Read More
Cystic Fibrosis Canada is thrilled to welcome Party City Canada as a new national partner. Party City has 50 stores in Canada and operates in every province excluding, PEI, Quebec and Manitoba. Cystic Fibrosis Canada is one of five non-profit organizations to benefit this year from the Party City CARES cause marketing campaign.Read More
MONTREAL, March 17th, 2016 /CNW Telbec/ - Laurent Pharmaceuticals Inc. announced today the closing of a financing round led by Cystic Fibrosis Canada. Existing investors Aligo Innovation LP (previously MSBi Valorisation) and members of Anges Quebec, as well as other existing and new private investors, also participated in the round.
This investment will allow the preparation of the upcoming Phase 2 clinical trial with LAU-7b in cystic fibrosis (CF) patients, planned to start later this year in Canada and United States. LAU-7b is a once-a-day oral drug addressing the persistent and unresolved inflammation, a leading cause of lung tissue destruction in CF.Read More
January 26, 2016 (Toronto, ON) ? Health Canada has issued a Notice of Compliance for the lumacaftor/ivacaftor combination drug PrORKAMBITM for use in Canada. This gives Canadians with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation a chance to gain access to this breakthrough treatment. PrORKAMBITM could benefit around 1,550 Canadians living with CF.Read More
A unique triple transplant has transformed the life of a 19-year-old Cystic Fibrosis patient who can now walk without an oxygen tank, exercise, eat full meals, and plan for the future.Read More
TORONTO, October 21, 2015 – SickKids Foundation is pleased to announce a newly formed partnership with Cystic Fibrosis Canada which sees the creation of the Program for Individualized Cystic Fibrosis (CF) Therapy. The partnership includes a multi-year commitment to raise $7.5 million in support of CF research conducted at the Peter Gilgan Centre for Research and Learning at SickKids. This generous support will help SickKids researchers accelerate the discovery of new treatments and determine the most effective, personalized therapies for CF patients.Read More